Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

cyclopia sequence 6Prostatic Neoplasms 6Neoplasm Metastasis 6Breast Neoplasms 6Lung Neoplasms 4Dyspnea 4Recurrence 3Primary Myelofibrosis 3Oropharyngeal Neoplasms 3Multiple Myeloma 3Esophageal Neoplasms 3Carcinoma, Squamous Cell 3Squamous Cell Carcinoma of Head and Neck 2Polycythemia Vera 2Pain 2Kidney Neoplasms 2Head and Neck Neoplasms 2Glioblastoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Thrombocythemia, Essential 1Splenomegaly 1Speech 1Sezary Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plexosarcoma 1Pathologic Complete Response 1

Interventions

Darbepoetin alfa 19Epoetin Alfa 17ACE-011 4Cyclosporine 3Busulfan 3luspatercept 2fludarabine phosphate 2fludarabine 2ferric carboxymaltose 2epoetin beta 2continuous erythropoietin receptor activator 2Methotrexate 2Iron-Dextran Complex 2Filgrastim 2Cyclophosphamide 2vactosertib 1thymoglobulin 1ruxolitinib 1roxadustat 1peginesatide 1pegfilgrastim 1niraparib 1leridistim 1iron isomaltoside 1000 1hematide 1ferric gluconate 1eltrombopag 1angiotensin I (1-7) 1Therapeutics 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anemia × Surveys and Questionnaires × Clear all
NCT02730884 2020-08-07

Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia

M.D. Anderson Cancer Center

Phase 2 Terminated
3 enrolled 6 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Leukemia, Splenomegaly, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡